Vivani Medical, the Healthcare sector company, was revisited by a Wall Street analyst on March 27. Analyst Naz Rahman from Maxim Group reiterated a Buy rating on the stock and has a $4.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Naz Rahman has given his Buy rating due to a combination of factors, starting with Vivani’s solid financial footing and visibility on funding. The company ended 2025 with a meaningful cash position, no debt, and additional committed equity capital that, in Rahman’s view, should comfortably support operations into mid-2027 and cover the next human clinical trial, reducing near-term financing risk.
Rahman also highlights strategic and clinical catalysts that could unlock substantial value. The planned Cortigent spin-off/IPO would crystallize the value of Vivani’s majority stake while providing non-dilutive funding, and the NPM-139 semaglutide implant program targets a large obesity market with a more convenient twice-yearly dosing schedule, leveraging an already well-understood drug profile and potentially enabling an efficient regulatory path, all of which underpin his constructive stance on the shares.